Trial
NCT03608033
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Omeros Corporation
Collaborators
—
Condition
IgA Nephropathy
Intervention
OMS721
Why stopped
IA did not meet the prespecified primary endpoint.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-09